Syros to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 27, 2024
Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, March 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
To access the live conference call, please dial (888) 259-6580 (domestic) or (416) 764-8624 (international) and refer to conference ID 21905455. A webcast of the call will also be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay of the webcast will be available for approximately 30 days following the call.
About Syros Pharmaceuticals
Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RAR? agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression. For more information, visit www.syros.com and follow us on Twitter (@SyrosPharma) and LinkedIn.
Organon today announced its results for the first quarter ended March 31, 2024.
"We entered this year with a clear focus: to deliver our 2024 financial targets while staying true to our mission of improving the health of women, and the first...
Lantern Pharma Inc. , an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced...
Quipt Home Medical Corp. (the "Company") ?, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, announced today that the Toronto Stock Exchange ("TSX") has accepted the Company's notice of intention to implement a...
Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will present long-term efficacy, safety and...
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced MedMatrix, a product in which it has a significant investment, has launched two new demonstration videos highlighting the capabilities of the MedMatrix AI Reporter and...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally...
